Skip to main content
. Author manuscript; available in PMC: 2023 Oct 3.
Published in final edited form as: Clin Cancer Res. 2023 Apr 3;29(7):1232–1242. doi: 10.1158/1078-0432.CCR-22-1973

Figure 5. CDCP1 expression is regulated by the RAS-Raf-MEK signaling pathway in BC.

Figure 5.

A. Diagram showing the RAS-Raf-MEK pathway downstream of receptor tyrosine kinase (RTK) signaling. The prevalence of molecular alterations (including mutations, structural variants and copy number alterations) in bladder cancer from cbioportal is indicated in the purple boxes. B. The prevalence of the most common RAS mutations in bladder cancer from cbioportal is indicated. C. Western blots showing total CDCP1 expression in UMUC3 cells treated with increasing concentrations of sotorasib, a KRAS G12C inhibitor. D. Flow cytometry data showing that cell surface CDCP1 expression after treatment with 1 or 10 μm sotorasib. E. Western blots showing total CDCP1 expression in UMUC3 cells treated with increasing concentrations of trametinib, a MEK inhibitor. F. Flow cytometry showing cell surface CDCP1 expression after treatment with 1 or 10 μm of trametinib.